Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Eureka Therapeutics Inc. maintains a focused presence in the Biotechnology & Pharmaceuticals technology area with 1 pending office action currently on the docket. This action is being handled by 1 distinct examiner within 1 distinct art unit, representing a concentrated prosecution environment. For a company in the Biotechnology & Pharmaceuticals sector, this level of focus means that the immediate legal strategy is tied to a specific technical niche within the patent office.
The examiner assigned to this workload is DUFFY, BRADLEY, who is currently managing 1 busiest examiner pending action for the firm. As the busiest examiner with 1 pending office action, DUFFY, BRADLEY holds the entirety of the company's active examination pipeline. This concentration in 1 distinct art unit simplifies the administrative tracking of the portfolio but also means that the outcome of the 1 pending office action will significantly impact the company's current patent objectives.
The alignment of 1 distinct examiner and the specific art unit suggests that the pending matter is being reviewed within a specific regulatory framework. Practitioners should focus on the specific preferences and past trends associated with DUFFY, BRADLEY to navigate the case effectively. This streamlined prosecution profile minimizes the complexity often found in larger, more distributed portfolios that involve multiple 1 busiest examiner pending actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUFFY, BRADLEY | 1 | 54.5% | +45.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18247864 | COMPOSITIONS TARGETING NDC80/MHC COMPLEXES AND USES THEREOF | DUFFY, BRADLEY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18247864 | COMPOSITIONS TARGETING NDC80/MHC COMPLEXES AND USES THEREOF | DUFFY, BRADLEY | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18247864 | COMPOSITIONS TARGETING NDC80/MHC COMPLEXES AND USES THEREOF | DUFFY, BRADLEY | 1643 | §102§112 | Non-Final OA | — | Pending | Apr 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial